title: The NEAT study: a 48-week open-label study to compare the antiviral efficacy and safety of GW433908 versus nelfinavir in antiretroviral therapy-naive HIV-1-infected patients.
abstract: OBJECTIVE
  To compare the efficacy, durability, and tolerability of GW433908 (908), 1400 mg twice-daily (BID), with nelfinavir (NFV), 1250 mg BID.
  
  
  METHODS
  This was an international, multicenter, randomized, open-label study (NEAT) in antiretroviral therapy (ART)-naive HIV-infected adults with plasma HIV-1 RNA (vRNA) at screening > or =5000 copies/mL (c/mL). Patients were randomly assigned to 908 or NFV (2:1) for a minimum of 48 weeks, with a background of abacavir (ABC) and lamivudine (3TC).
  
  
  RESULTS
  A total of 166 patients received randomized treatment with 908 BID and 83 received NFV BID. The population was diverse with regard to race and gender (76% Hispanics and blacks, 31% female) and had advanced HIV disease at screening (45% had vRNA >100,000 c/mL, 48% had CD4 cell counts <200 cells/mm3, 20% had a history of Centers for Disease Control class C events). After 48 weeks of study by an intention-to-treat rebound or discontinuation = failure analysis, a greater proportion of patients in the 908 BID group (66%) than the NFV BID group (51%) achieved vRNA <400 c/mL. Furthermore, more patients with screening vRNA >100,000 c/mL (67 vs. 35%) or CD4 <50 cells/mm3 (48 vs. 24%) achieved undetectable viral loads taking 908 BID compared with NFV BID, respectively. Favorable immunologic responses were observed for both groups. Diarrhea, which was more common in the NFV BID group (18 vs. 5%), was the only drug-related grade 2-4 adverse event with a significant difference (P = 0.002) in incidence between groups.
  
  
  CONCLUSIONS
  Administration of 908 BID resulted in a potent and sustained antiretroviral response, notably in ART-naive patients with advanced HIV disease. GW433908 was generally well tolerated and provides a convenient dosing option without food or fluid restrictions.
authors.affiliation: Centro de Vacunas y Tratamiento de Enfermedades Febriles, Centro Especializado y Hospital Pediátrico San Fernando, La Sabana, Panama.
authors.forename: Amalia
authors.initials: A
authors.lastname: Rodriguez-French
authors.forename: Jack
authors.initials: J
authors.lastname: Boghossian
authors.forename: Glenda E
authors.initials: GE
authors.lastname: Gray
authors.forename: Jeffrey P
authors.initials: JP
authors.lastname: Nadler
authors.forename: Arnaldo R
authors.initials: AR
authors.lastname: Quinones
authors.forename: Gladys E
authors.initials: GE
authors.lastname: Sepulveda
authors.forename: Judith M
authors.initials: JM
authors.lastname: Millard
authors.forename: Paul G
authors.initials: PG
authors.lastname: Wannamaker
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D002219:Carbamates; D015224:Dideoxynucleosides / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D005663:Furans; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000276:immunology; D015497:HIV-1 / Q000276:immunology / Q000302:isolation & purification; D006801:Humans; D019259:Lamivudine / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D019888:Nelfinavir / Q000009:adverse effects / Q000627:therapeutic use*; D010755:Organophosphates / Q000009:adverse effects / Q000627:therapeutic use*; D012367:RNA, Viral / Q000097:blood; D018894:Reverse Transcriptase Inhibitors / Q000008:administration & dosage; D013449:Sulfonamides / Q000009:adverse effects / Q000627:therapeutic use*; D000099227:Abacavir
chemical_list: D019380:Anti-HIV Agents; D002219:Carbamates; D015224:Dideoxynucleosides; D005663:Furans; D019259:Lamivudine; D019888:Nelfinavir; D010755:Organophosphates; D012367:RNA, Viral; D018894:Reverse Transcriptase Inhibitors; D013449:Sulfonamides; D000099227:Abacavir; C426859:fosamprenavir